Even in the face of disturbing developments concerning its experimental anti-clotting drug Vorapaxar, pharmaceutical giant Merck has shown a disturbing intent to proceed with development of this dangerous product. Vorapaxar was once considered the most important drug in the development pipeline. In fact, as recently as 2009, Wall Street analysts predicted that the drug could… Read More